
Please try another search
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has BAVARIAN NORDIC (BVNRY) been one of those stocks this year? Let's take a closer look at the stock's year-to-date performance to find out.
BAVARIAN NORDIC is a member of our Medical group, which includes 899 different companies and currently sits at #3 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. BVNRY is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for BVNRY's full-year earnings has moved 742.86% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Our latest available data shows that BVNRY has returned about 7.91% since the start of the calendar year. In comparison, Medical companies have returned an average of -17.57%. This shows that BAVARIAN NORDIC is outperforming its peers so far this year.
To break things down more, BVNRY belongs to the Medical - Biomedical and Genetics industry, a group that includes 385 individual companies and currently sits at #97 in the Zacks Industry Rank. Stocks in this group have lost about 17.53% so far this year, so BVNRY is performing better this group in terms of year-to-date returns.
Investors in the Medical sector will want to keep a close eye on BVNRY as it attempts to continue its solid performance.
Two weeks ago, the rumor mill ramped up again about the potential restructuring of Intel Corporation (NASDAQ:INTC). The probing balloons centered around Taiwan Semiconductor...
More than a century ago, then-Representative William McKinley pursued an aggressive tariff strategy that sought to protect American industry and reduce reliance on foreign...
Early in 2025, value stocks emerged as a popular choice among investors seeking market-beating returns. However, factor-based investing strategies can be notoriously difficult to...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.